Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
1. Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
Herchuelz
A
A
Unité de Pharmacologie Clinique, Hôpital Vésale, Montigny-le-Tilleul France.
Gangji
D
D
Derenne
F
F
Jeanniot
J P
JP
Douchamps
J
J
D000328:Adult; D015765:Almitrine / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D010641:Phenotype; D011110:Polymorphism, Genetic; D013034:Sparteine / Q000378:metabolism*
D013034:Sparteine; D015765:Almitrine; D003647:Debrisoquin